A dated log of what changed in this market. 28 items, newest October 15, 2026. Every entry names its source; where a figure has been withdrawn, the corrections log says so.
Updated as sources change, not on a schedule. The most recent item is dated October 15, 2026.
OIRA logged FDA’s “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94) on October 14. Its text is not public; press reports say it could allow temporary compounding of BPC-157 and others. Confidence: confirmed (listing); contents reported.
NexLife now lists $139/$119 on 12-month plans, Eden a flat $129/$99 with no membership, and Mochi prices by dose. bmiMD, Hims, Hers and Ro could not be re-read. Confidence: confirmed.
Median lowest monthly price: sermorelin injection $131, NAD+ injection $129, glutathione $99. Only one public BPC-157 price: $399 a month. Confidence: confirmed.
CNBC reports the largest U.S. private employer will add the two drugs at no cost for diabetes after prior authorization. Weight-loss GLP-1s stay excluded, so affected employees remain in the cash-pay market. Confidence: reported (CNBC).
A paid press release describes quarterly-billed plans with B12 additives. We have not read Ozari’s own price pages, so it is not in our dataset. Confidence: reported (company release).
Court dockets show five complaints filed October 8 against peptide vendors and clinics, after six filed August 12. Retatrutide is investigational; anything sold under that name is unapproved. Confidence: confirmed (dockets).
Letters 737806 and 737810 (dated Sept 23 and 24, posted Oct 6) cite “Semanat” and “Semanext” injections. Online “generic semaglutide” is not a legitimate low-cost option. Confidence: confirmed.
FDA’s GLP-1 page (current Oct 1) also sets a 28-day discard rule for compounded multi-dose vials and counts 990 adverse-event reports for compounded semaglutide and more than 730 for tirzepatide to May 31. Confidence: confirmed.
Coverage for diabetes and other approved uses continues. Affected members move to self-pay or stop. Confidence: confirmed.
Eligible Part D enrollees pay $50 a month for covered brand GLP-1s; the BALANCE model will not launch in Medicare in 2027. Open enrollment runs October 15 to December 7. Confidence: confirmed.
Letter 738238 (dated Sept 18) says the additive versions “appear to be essentially copies” of approved drugs and cites insanitary conditions. Expect pharmacy or formulation changes at programs that used Empower. Confidence: confirmed.
Novo’s capital markets day deck puts cash pay at the center of the pill’s U.S. launch, with partnerships across nine-plus telehealth companies. Confidence: confirmed.
Letters dated August 24 name retatrutide, semaglutide, tirzepatide, tesamorelin, PT-141 and others as unapproved drugs, and reject the research-use label as a defence. Confidence: confirmed.
Semaglutide now runs $60 to $99 and tirzepatide $90 to $199 a month by dose, plus membership. Post updated September 18. Confidence: confirmed.
Cases were filed in Texas and California federal courts. Lilly says it has referred more than 200 sellers to authorities. Confidence: confirmed (dockets).
Non-binding votes on July 23 and 24; DSIP was rejected. No listing has been proposed. Full status in our October report. Confidence: vote press-reported.
The foundational patent expired 20 March 2026 in four markets and lapsed in Canada, which approved its first two generics in April and May.
FDA moved BPC-157 out of Category 2 in April 2026 after its nomination was withdrawn. It is not on the 503A bulks list, so no lawful 503A compounding route exists, and it has no human efficacy trials.
The manufacturer's own price guide sets the oral tablet at $149 for 1.5 and 4 mg and $299 for the 9 and 25 mg maintenance doses. The 4 mg rate ends 31 August 2026.
Medicaid coverage of the obesity indication is a state-by-state decision, and many programmes cover GLP-1s for diabetes while excluding obesity.
State board registers, FDA warning letters, the 503B list and openFDA recalls are all searchable by company name — which is why a provider that will not name its pharmacy has ended the conversation.
The STEP-1 extension and SURMOUNT-4 both report regain on withdrawal. If treatment is ongoing, annual maintenance cost is the figure that matters.
Membership fees outside the headline, dose tiers, introductory rates and prepay-only pricing. They stack, and all four are visible if you ask four questions.
The mass-compounding pathway closed on 21 February 2025. 503A patient-specific compounding continues, and it requires a documented clinical reason.
A generic referencing Victoza was approved in December 2024 and one referencing Saxenda in August 2025. It is the cheapest approved route and the least effective.
Gastrointestinal effects cluster around each dose increase. In STEP-1, nausea affected roughly 44% against about 18% on placebo, and about 7% discontinued.
Egrifta is approved for excess visceral abdominal fat in HIV-associated lipodystrophy. It is not approved for general fat loss, body recomposition or anti-ageing.
Anaesthesia guidance exists because case reports described residual gastric contents after adequate fasting. It applies to compounded products too.